Skip to Main Content

For the second time, the Food and Drug Administration rejected an Intarcia Therapeutics implant aimed at treating type 2 diabetes, the company said Tuesday.

“We are extremely disappointed,” Intarcia spokesperson Sunny Uberoi told STAT in a statement. “We remain steadfast in our belief that [the implant] holds important potential as a new treatment option for people managing type 2 diabetes.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!